(ALMDT) Mediantechn - Overview
Sector: Healthcare | Industry: Medical Devices | Exchange: PA (France) | Market Cap: 217m EUR | Total Return: 149.6% in 12m
Avg Turnover: 1.03M
Warnings
Negative Equity with losses - insolvent profile
Share dilution 75.4% YoY
Interest Coverage Ratio -2.1 is critical
Altman Z'' -14.94 < 1.0 - financial distress zone
Volatile
Tailwinds
Rs Leader, Idiosyncratic Leader, Tailwind, Pullback 52w
Median Technologies SA (ALMDT) is a French health technology firm specializing in AI-powered medical imaging solutions for oncology. The company operates across two primary segments: clinical trial services (iCRO and iSee) and diagnostic software development (eyonis). Its business model focuses on providing standardized imaging biomarkers to pharmaceutical companies for drug development and non-invasive diagnostic tools for clinical patient care.
The company operates within the high-growth intersection of oncology and medical imaging, where AI is increasingly utilized to reduce human error in tumor measurement and improve early detection rates. Median Technologies maintains a global footprint with significant operations in the United States and China, targeting both the multi-billion dollar Clinical Research Organization (CRO) market and the evolving cancer screening sector.
For a deeper look into the companys fundamentals and historical performance, you may find ValueRays detailed analytics helpful.
- iCRO clinical trial service revenue growth and backlog execution
- FDA clearance and commercialization timeline for eyonis lung cancer screening
- Cash burn rate and capital requirements for AI product development
- Global oncology R&D spending by pharmaceutical and biotechnology clients
| Net Income: -59.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: -1.86 > 0.02 and ΔFCF/TA -89.92 > 1.0 |
| NWC/Revenue: -33.27% < 20% (prev 26.98%; Δ -60.25% < -1%) |
| CFO/TA -0.99 > 3% & CFO -35.4m > Net Income -59.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 0.67 > 1.5 & < 3 |
| Outstanding Shares: last quarter (36.7m) vs 12m ago 75.40% < -2% |
| Gross Margin: -77.59% > 18% (prev -0.48%; Δ -7.71k% > 0.5%) |
| Asset Turnover: 129.2% > 50% (prev 93.99%; Δ 35.21% > 0%) |
| Interest Coverage Ratio: -2.11 > 6 (EBITDA TTM -42.4m / Interest Expense TTM 21.6m) |
| A: -0.43 (Total Current Assets 31.4m - Total Current Liabilities 46.8m) / Total Assets 35.9m |
| B: -0.95 (Retained Earnings -34.1m / Total Assets 35.9m) |
| C: -1.27 (EBIT TTM -45.6m / Avg Total Assets 35.8m) |
| D: -0.45 (Book Value of Equity -32.2m / Total Liabilities 71.0m) |
| Altman-Z'' = -14.94 = D |
| DSRI: 0.69 (Receivables 8.88m/9.38m, Revenue 46.3m/33.7m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 1.07 (AQ_t 0.06 / AQ_t-1 0.06) |
| SGI: 1.38 (Revenue 46.3m / 33.7m) |
| TATA: -0.67 (NI -59.3m - CFO -35.4m) / TA 35.9m) |
| Beneish M = -3.66 (Cap -4..+1) = AAA |
As of May 27, 2026, the stock is trading at EUR 5.64 with a total of 602,419 shares traded.
Over the past week, the price has changed by +8.67%,
over one month by +10.16%,
over three months by +9.09% and
over the past year by +149.56%.
Mediantechn has no consensus analysts rating.
P/S = 9.2472
P/B = 252.6595
Revenue TTM = 46.3m EUR
EBIT TTM = -45.6m EUR
EBITDA TTM = -42.4m EUR
Long Term Debt = 18.0m EUR (from longTermDebt, last quarter)
Short Term Debt = 2.35m EUR (from shortTermDebt, last quarter)
Debt = 24.0m EUR (from shortLongTermDebtTotal, last quarter) + Leases 2.19m
Net Debt = 5.55m EUR (calculated: Debt 24.0m - CCE 18.4m)
Enterprise Value = 222.6m EUR (217.0m + Debt 24.0m - CCE 18.4m)
Interest Coverage Ratio = -2.11 (Ebit TTM -45.6m / Interest Expense TTM 21.6m)
EV/FCF = -3.33x (Enterprise Value 222.6m / FCF TTM -66.8m)
FCF Yield = -30.02% (FCF TTM -66.8m / Enterprise Value 222.6m)
FCF Margin = -144.3% (FCF TTM -66.8m / Revenue TTM 46.3m)
Net Margin = -128.1% (Net Income TTM -59.3m / Revenue TTM 46.3m)
Gross Margin = -77.59% ((Revenue TTM 46.3m - Cost of Revenue TTM 82.2m) / Revenue TTM)
Gross Margin QoQ = -79.74% (prev -42.60%)
Tobins Q-Ratio = 6.20 (Enterprise Value 222.6m / Total Assets 35.9m)
Interest Expense / Debt = 90.29% (Interest Expense 21.6m / Debt 24.0m)
Taxrate = 25.0% (EU avg default 25%)
NOPAT = -34.2m (EBIT -45.6m * (1 - 25.00%)) [loss with tax shield]
Current Ratio = 0.63 (Total Current Assets 31.4m / Total Current Liabilities 50.1m)
Debt / Equity = -0.68 (negative equity) (Debt 24.0m / totalStockholderEquity, last quarter -35.2m)
Debt / EBITDA = -0.13 (negative EBITDA) (Net Debt 5.55m / EBITDA -42.4m)
Debt / FCF = -0.08 (negative FCF - burning cash) (Net Debt 5.55m / FCF TTM -66.8m)
Total Stockholder Equity = -32.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -165.5% (out of range, set to none)
RoE = -5.07k% (out of range, set to none) (Net Income TTM -59.3m / Total Stockholder Equity 1.17m)
RoCE = -237.6% (out of range, set to none) (EBIT -45.6m / Capital Employed (Equity 1.17m + L.T.Debt 18.0m))
RoIC = 126.9% (negative operating profit) (NOPAT -34.2m / Invested Capital -26.9m)
WACC = 9.42% (E(217.0m)/V(241.0m) * Re(10.46%) + (debt cost/tax rate unavailable))
Discount Rate = 10.46% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 82.22 | Cagr: 50.10%
[DCF] Fair Price = unknown (Cash Flow -66.8m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -1.19 | # QB: -2
Revenue Correlation: 89.09 | Revenue CAGR: 1.98% | SUE: -0.01 | # QB: 0
EPS current Year (2026-12-31): EPS=-0.47 | Chg30d=-12.50% | Revisions=+20% | GrowthEPS=+49.2% | GrowthRev=+15.3%
EPS next Year (2027-12-31): EPS=-0.39 | Chg30d=-207.81% | Revisions=+20% | GrowthEPS=+17.5% | GrowthRev=+32.9%
[Analyst] Revisions Ratio: +20%